Novo Nordisk reports analyses of SUSTAIN trials of Ozempic

Ozempic consistently reduced the risk of the composite outcome of time to first occurrence of non-fatal heart attack, non-fatal stroke or cardiovascular death – collectively termed major adverse cardiovascular events, MACE – in people with type 2 diabetes at high cardiovascular risk regardless of previously having had a cardiovascular event at the start of the trial, announced Novo Nordisk. Findings from two post-hoc subgroup analyses of the SUSTAIN 6 trial and one post-hoc meta-analysis of MACE in the SUSTAIN 1-5 trials were presented at the ESC Congress 2018, organized by the European Society of Cardiology. Professor Stephen Bain, School of Medicine, Swansea University, said, “We have seen from clinical trials that diabetes treatments confer variable effects on cardiovascular outcomes and the results of these post-hoc analyses provide further evidence of the consistent cardiovascular risk reduction of Ozempic in people with type 2 diabetes, with varying profiles of cardiovascular risk at baseline.”

https://bit.ly/2Nrm8RC